| Sandia Ridge Center | |
| 2216 Lester Drive Ne, Albuquerque, New Mexico 87112 | |
| (505) 296-4808 | |
| Name | Sandia Ridge Center |
|---|---|
| Location | 2216 Lester Drive Ne, Albuquerque, New Mexico |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 140 |
| Occupancy Rate | 84% |
| Medicare ID (CCN) | 325032 |
| Legal Business Name | St. John Healthcare And Rehabilitation Center, Llc |
| Ownership Type | For Profit - Individual |
| NPI Number | 1447442512 |
| Organization Name | ST. JOHN HEALTHCARE AND REHABILITATION CENTER, LLC |
| Doing Business As | ST. JOHN HEALTHCARE AND REHABILITATION CENTER |
| Address | 2216 Lester Dr Ne, Albuquerque, NM 87112 |
| Phone Number | 505-296-4808 |
News Archive
A simple marker on eye examination may help vision care professionals predict which patients will have a higher or lower rate of problems after starting extended-wear contact lenses, reports a study in the April issue of Optometry and Vision Science, the official journal of the American Academy of Optometry. The journal is published by Wolters Kluwer.
Epocrates, Inc. today announced the pricing of the initial public offering of 5,360,000 shares of its common stock at a price to the public of $16.00 per share. The shares are expected to begin trading today on the NASDAQ under the ticker symbol "EPOC." Epocrates is offering 3,574,285 shares and selling stockholders are offering the remaining 1,785,715 shares.
In a newly published paper, the authors first paint the vision of what optimal patient advocacy can do to overcome the challenges described by kidney transplant patients and donors and then describe how to make that vision a reality, especially during the COVID-19 pandemic.
NewYork-Presbyterian and Weill Cornell Medicine have begun the first clinical trial in the United States that uses a small molecule to treat men with progressive prostate cancer that has spread beyond the prostate and is no longer responding to hormonal therapy.
Existing microscopy-based methods of detecting apoptosis, such as TUNEL (terminal deoxynucleotidyl transferase dUTP nick-end labeling), have limited quantitative capabilities due to insufficient signal-to-noise ratios.
› Verified 2 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
A simple marker on eye examination may help vision care professionals predict which patients will have a higher or lower rate of problems after starting extended-wear contact lenses, reports a study in the April issue of Optometry and Vision Science, the official journal of the American Academy of Optometry. The journal is published by Wolters Kluwer.
Epocrates, Inc. today announced the pricing of the initial public offering of 5,360,000 shares of its common stock at a price to the public of $16.00 per share. The shares are expected to begin trading today on the NASDAQ under the ticker symbol "EPOC." Epocrates is offering 3,574,285 shares and selling stockholders are offering the remaining 1,785,715 shares.
In a newly published paper, the authors first paint the vision of what optimal patient advocacy can do to overcome the challenges described by kidney transplant patients and donors and then describe how to make that vision a reality, especially during the COVID-19 pandemic.
NewYork-Presbyterian and Weill Cornell Medicine have begun the first clinical trial in the United States that uses a small molecule to treat men with progressive prostate cancer that has spread beyond the prostate and is no longer responding to hormonal therapy.
Existing microscopy-based methods of detecting apoptosis, such as TUNEL (terminal deoxynucleotidyl transferase dUTP nick-end labeling), have limited quantitative capabilities due to insufficient signal-to-noise ratios.
› Verified 2 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 2 |
| Total Amount of Fines in Dollars | $52899 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 2 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 33.43 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 14.17 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 28.85 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.83 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 0.74 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 9.21 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 1.18 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 85.82 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 25.65 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 58.14 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 1.76 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 43.13 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 13.42 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 7.93 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 96.2 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 66.77 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 46.3 | 82.93 |
News Archive
A simple marker on eye examination may help vision care professionals predict which patients will have a higher or lower rate of problems after starting extended-wear contact lenses, reports a study in the April issue of Optometry and Vision Science, the official journal of the American Academy of Optometry. The journal is published by Wolters Kluwer.
Epocrates, Inc. today announced the pricing of the initial public offering of 5,360,000 shares of its common stock at a price to the public of $16.00 per share. The shares are expected to begin trading today on the NASDAQ under the ticker symbol "EPOC." Epocrates is offering 3,574,285 shares and selling stockholders are offering the remaining 1,785,715 shares.
In a newly published paper, the authors first paint the vision of what optimal patient advocacy can do to overcome the challenges described by kidney transplant patients and donors and then describe how to make that vision a reality, especially during the COVID-19 pandemic.
NewYork-Presbyterian and Weill Cornell Medicine have begun the first clinical trial in the United States that uses a small molecule to treat men with progressive prostate cancer that has spread beyond the prostate and is no longer responding to hormonal therapy.
Existing microscopy-based methods of detecting apoptosis, such as TUNEL (terminal deoxynucleotidyl transferase dUTP nick-end labeling), have limited quantitative capabilities due to insufficient signal-to-noise ratios.
› Verified 2 days ago
Sandia Ridge Center Location: 2216 Lester Drive Ne, Albuquerque, New Mexico 87112 Phone: (505) 296-4808 | |
The Rehabilitation Center Of Albuquerque Location: 5900 Forest Hills Drive Ne, Albuquerque, New Mexico 87109 Phone: (505) 822-6000 | |
Las Palomas Center Location: 8100 Palomas Avenue Ne, Albuquerque, New Mexico 87109 Phone: (505) 821-4200 | |
Uptown Rehabilitation Center Location: 7900 Constitution Avenue Ne, Albuquerque, New Mexico 87110 Phone: (505) 296-5565 |